Modern high-dose therapy with autologous bone marrow transplantation (ABMT) used for the management of Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL) began about a decade ago. ABMT may avoid the problems of findings a suitable donor for transplantation and graft-versus-host disease while eradicating a disease or providing long-term, disease-free survival to patients. Outcome depends on the grade of the disease. Efforts to reduce the morbidity and mortality associated with high-dose therapy, to identify the optimal high-dose therapy for each histologic type of lymphoma, and to better identify those patients most likely to benefit continue.
|Original language||English (US)|
|Number of pages||11|
|Journal||Hematology/Oncology Clinics of North America|
|State||Published - Jan 1 1990|
ASJC Scopus subject areas